Denmark's medicines regulator. It licenses medicines for the Danish market, authorises clinical trials, monitors side effects and decides which prescription medicines are eligible for reimbursement; new cancer medicines are approved for Denmark through the EU's centralised procedure.
The Danish Medicines Agency, at Axel Heides Gade 1 in Copenhagen, has around 650 employees. By its own description it authorises and inspects pharmaceutical companies and licenses medicinal products in the Danish market, monitors adverse reactions, authorises clinical trials, decides which medicines are eligible for reimbursement, monitors medical devices, and appoints and supervises pharmacies; it does most of this in cooperation with the other EU regulators. The coordinates are an approximate street point.
New medicines with a new active substance for cancer must be evaluated by the European Medicines Agency under the EU centralised procedure, and the resulting authorisation covers Denmark. The Agency also sets the reimbursement steps for prescription medicines bought at a pharmacy: in 2026 an adult pays the full price for the first 1,135 kroner in a twelve-month period, with 50%, 75% and 85% reimbursement above that, and full reimbursement once spending passes 22,596 kroner, so that the most an adult pays in co-payment is 4,850 kroner. Terminally ill patients who choose to spend their last time at home or in a hospice can have prescribed medicine expenses covered.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-11-19.
Matched to Danish Medicines Agency, including child institutions. 5 works · 68 citations · 100% open access · 40% clinical trials · 0% reviews.
| Work | Journal | Year | Citations |
|---|---|---|---|
| Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases 10.1038/s41434-025-00586-x · open access | Gene Therapy | 2025 | 24 |
| Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms 10.1038/s41416-024-02773-w · open access | British Journal of Cancer | 2024 | 22 |
| Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials 10.1016/j.jval.2023.06.019 · open access | Value in Health | 2023 | 11 |
| NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms 10.1111/jne.13428 · open access | Journal of Neuroendocrinology | 2024 | 9 |
| A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors 10.1080/20018525.2023.2194162 · open access | European Clinical Respiratory Journal | 2023 | 2 |
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/